|
September 11, 2006
|
Affinergy Signs Exclusive Development & License Agreement with Synthes
RESEARCH TRIANGLE PARK, N.C., September 11, 2006 - Affinergy, Inc., a Duke University spinout with a proprietary site-specific biological delivery system, announced that it has entered into a multi-year development and license agreement with Synthes. Affinergy will work exclusively with Synthes on multiple product applications across the Spine, Trauma and Craniomaxillofacial markets.
"Synthes built its leadership position in the orthopedics market by continually providing innovative products," said Peyton Anderson, Affinergy's CEO. "Affinergy is very excited by the potential of these development programs to improve patient outcomes while better serving the surgeons' clinical practices. The market leading position of Synthes is an excellent platform to leverage the full potential of Affinergy's technology."
Hansjörg Wyss, Synthes Chairman and CEO, added "Synthes is very excited about the collaboration with Affinergy on this long-term biomaterials development program."
About Affinergy, Inc.
Affinergy develops site-specific biological systems using biofriendly linkers that selectively adhere to proteins, drugs, cells, and biomaterial surfaces in order to kickstart biology toward an intended outcome. Affinergy is focused on developing coatings and medical devices for the orthopedic and cardiovascular markets. Affinergy's technology was patented at Duke University and was awarded 2005 Innovation of the Year by Frost & Sullivan in the category of Medical Device Coatings. For more information, visit www.affinergy.com.
About Synthes
Synthes is a leading global medical device company. We develop, produce and market instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues. For more information, visit www.synthes.com.
For more information:
Peyton Anderson
Chief Executive Officer
Affinergy, Inc.
919-433-2229
panderson@affinergy.com
|
